OR WAIT 15 SECS
© 2020 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2020 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Particle engineering can manipulate APIs into manufacturable forms.
Online sessions on excipient characterization, extended-release formation, novel excipients, formulation strategies, and more.
Taste-masking can ensure success of a drug product, particularly those targeted to pediatric or geriatric populations.
Excipients must be carefully chosen to ensure optimum protection for vaccines and live biotherapeutic products.
October 29, 2020
Two FDA-funded projects at RCPE will look at real-time monitoring and control of drug tablet coating and developing a digital twin for drug production control.
October 20, 2020
Orgenesis has completed its previously announced acquisition of Koligo Therapeutics with the additional acquisition of Tissue Genesis’ cell isolation technology, Icellator.
October 16, 2020
AFI representatives of the process validation working group explore and define key elements for an enhanced approach to process validation for sterile liquid and freeze-dried forms.
AFI representatives of the process validation working group explore and define key elements for an enhanced approach to process validation for solid oral dosage forms.
October 15, 2020
The IQ Consortium marks a decade of impactful innovation of collaboration through a network of pharmaceutical companies driving change for the bio/pharmaceutical industry.
October 07, 2020
Schott and Credence MedSystems have formed a strategic collaboration to make syringe injections safer.
October 03, 2020
More complex and challenging compounds require a more tailored approach to formulation strategies.
Taste-masking can be of significant importance in ensuring success of a drug product, particularly those targeted to pediatric or geriatric populations.
October 01, 2020
The acquisition will support the accelerated commercialization of Kyslecel (autologous pancreatic islets), Koligo’s personalized cell therapy for treating pancreatitis.
The OneXpress solution is designed to accelerate oral dosage drug development and manufacturing.
September 22, 2020
Moderna and Chiesi Group are collaborating on the discovery and development of mRNA therapeutics to treat pulmonary arterial hypertension.
September 18, 2020
The collaboration will expand the manufacturing capacity for lenzilumab, a COVID-19 therapeutic candidate, in advance of a potential Emergency Use Authorization in 2020.
The agreement will Increase global manufacturing capacity for Novavax’s vaccine candidate, NVX-CoV2373, to more than two-billion annualized doses when at full capacity in 2021.
The agreement between the two companies will significantly increase global supply capacity for Lilly's potential COVID-19 treatments.
September 15, 2020
The companies will focus on the development and commercialization of Seattle Genetics’ ladiratuzumab vedotin and TUKYSA (tucatinib).
September 09, 2020
Catalent’s Redwood Bioscience subsidiary will develop antibody-drug conjugates (ADCs) for Exelixis using Catalent’s proprietary SMARTag site-specific bioconjugation technology.
September 08, 2020
As public confidence in the drug development process waivers, leading vaccine developers promise to adhere to scientific and regulatory principles.
September 03, 2020
Risk-based decision-making is impacting all aspects of manufacturing quality from raw material supply to facility inspections.
Tight development timelines and accelerated approval pathways favor simple, cost-effective capsule formulations.